TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
Fiche publication
Date publication
mai 2016
Journal
Radiology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Ye SL, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R
Lien Pubmed
Résumé
To evaluate transarterial chemoembolization (TACE) use prior to and concomitantly with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) across different global regions.
Mots clés
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, therapeutic use, Carcinoma, Hepatocellular, therapy, Chemoembolization, Therapeutic, methods, Combined Modality Therapy, Disease Progression, Female, Humans, Liver Neoplasms, therapy, Male, Middle Aged, Niacinamide, analogs & derivatives, Phenylurea Compounds, therapeutic use, Survival Rate, Treatment Outcome
Référence
Radiology. 2016 May;279(2):630-40